Physician profile
Richard Rivera
NPI 1710952577
$4,286.29
in general payments reported to CMS, 2019-2025
26 companies · $392 in 2025
The $392 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $512 · 2021: $452 · 2022: $975 · 2023: $1,006 · 2024: $625 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,023.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,023.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,022.89 | 2019-2025 | Farxiga, Breztri, Fasenra |
| Abbvie INC. | $751.76 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $691.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $415.61 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $318.22 | 2019-2024 | |
| Pfizer INC. | $143.51 | 2021-2025 | |
| Organon LLC | $102.70 | 2022-2025 | Nexplanon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.72 | 2019-2024 | Xifaxan |
| Exact Sciences Corporation | $77.04 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $68.97 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $61.66 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.80 | 2023-2024 | Synjardy, Tradjenta, Jardiance |
| Glaxosmithkline, LLC. | $58.53 | 2019-2025 | Shingrix, Arexvy |
| Amgen INC. | $50.71 | 2020-2023 | Otezla, Repatha |
| Allergan, INC. | $50.03 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $48.84 | 2022-2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $45.55 | 2019 | |
| Hologic Sales and Service, LLC | $41.48 | 2022 | |
| Aimmune Therapeutics, INC. | $38.52 | 2024-2025 | Zenpep |
| Astellas Pharma US INC | $28.68 | 2024 | Veozah |
| Ossur Americas, INC. | $24.09 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.00 | 2023 | |
| Xeris Pharmaceuticals, INC. | $21.92 | 2020 | |
| Eisai INC. | $19.90 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $18.26 | 2021 | |
| Genentech USA, INC. | $15.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.